Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Evan Massi"'
Autor:
Peter S. Lee, Katherine G. MacDonald, Evan Massi, Pamela V. Chew, Christine Bee, Padma Perkins, Bryant Chau, Kent Thudium, Jack Lohre, Pradyot Nandi, Ekaterina G. Deyanova, Ishita Barman, Olafur Gudmundsson, Gavin Dollinger, Tim Sproul, John J. Engelhardt, Pavel Strop, Arvind Rajpal
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Although therapeutically efficacious, ipilimumab can exhibit dose-limiting toxicity that prevents maximal efficacious clinical outcomes and can lead to discontinuation of treatment. We hypothesized that an acidic pH-selective ipilimumab (pH Ipi), whi
Externí odkaz:
https://doaj.org/article/691eb159503a4399a519acfc7748ae85
Autor:
Neil P. Shah, Gideon Bollag, Brian L. West, Gaston Habets, Henry H. Hsu, Mai H. Le, Prabha N. Ibrahim, Wayne Spevak, Jiazhong Zhang, Bernice Matusow, Elizabeth A. Burton, Ben Powell, Heidi Carias, Garson Tsang, Rafe Shellooe, Andrew Kasarskis, Alexander Perl, Robert Sebra, Ali Bashir, Matthew Pendleton, Lauren E. Damon, Evan Massi, Ying Zhang, Elisabeth A. Lasater, Kimberly C. Lin, Chao Zhang, Catherine C. Smith
Supplementary Table 1. Crystallographic Data and Refinement statistics. Supplementary Table 2. Comparing Target Inhibition by Quizartinib and PLX3397 in Engineered Ba/F3 cells Expressing FLT3-ITD, FLT3-ITD/F691L and FLT3-ITD/D835Y. Supplementary Tabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f3238bc9253c505ce861afdefa65ccf
https://doi.org/10.1158/2159-8290.22531562.v1
https://doi.org/10.1158/2159-8290.22531562.v1
Autor:
Neil P. Shah, Ross L. Levine, Barry S. Taylor, Gideon Bollag, Brian West, Mai H. Le, Henry H. Hsu, Theodore C. Tarver, Elli Papaemmanuil, Juan S. Medina-Martinez, Matthieu Najm, Franck Rapaport, Nicholas D. Socci, Cyriac Kandoth, Evan Massi, Aaron D. Viny, Catherine C. Smith
Purpose:Biomarkers of response and resistance to FLT3 tyrosine kinase inhibitors (TKI) are still emerging, and optimal clinical combinations remain unclear. The purpose of this study is to identify co-occurring mutations that influence clinical respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89d67214d6a1910af12b296f5a771aeb
https://doi.org/10.1158/1078-0432.c.6530567
https://doi.org/10.1158/1078-0432.c.6530567
Autor:
Neil P. Shah, Ross L. Levine, Barry S. Taylor, Gideon Bollag, Brian West, Mai H. Le, Henry H. Hsu, Theodore C. Tarver, Elli Papaemmanuil, Juan S. Medina-Martinez, Matthieu Najm, Franck Rapaport, Nicholas D. Socci, Cyriac Kandoth, Evan Massi, Aaron D. Viny, Catherine C. Smith
Supplemental Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::160fb9940590a640a855d9865032f993
https://doi.org/10.1158/1078-0432.22480967.v1
https://doi.org/10.1158/1078-0432.22480967.v1
Autor:
Elli Papaemmanuil, Mai H. Le, Catherine C. Smith, Nicholas D. Socci, Brian L. West, Franck Rapaport, Ross L. Levine, Matthieu Najm, Evan Massi, Juan S. Medina-Martinez, Neil P. Shah, Henry H. Hsu, Theodore C. Tarver, Aaron D. Viny, Gideon Bollag, Barry S. Taylor, Cyriac Kandoth
Publikováno v:
Clin Cancer Res
Purpose: Biomarkers of response and resistance to FLT3 tyrosine kinase inhibitors (TKI) are still emerging, and optimal clinical combinations remain unclear. The purpose of this study is to identify co-occurring mutations that influence clinical resp
Autor:
James Lim, Albert Wong, Ann Lu, Candy Garcia, Evan Massi, Yewei Xing, Ningchun Liu, Scott Wise
Publikováno v:
Cancer Research. 83:589-589
The tumor microenvironment (TME) has several characteristics that distinguish it from normal tissue, including elevated interstitial fluid pressures and hypoxia. To study the effects of TME culture conditions, commonly used target cell lines were ser
Autor:
Yelena Bronevetsky, Evan Massi, Candy Garcia, Ningchun Liu, Yewei Xing, Natalie Czeryba, Scott Wise, James Lim
Publikováno v:
Cancer Research. 83:1782-1782
Chimeric antigen receptor (CAR) T cell therapy holds great promise for the treatment of various cancers, including solid tumors. However, attempts to model the behavior and effectiveness of CAR-T cell therapies for blood cancers and solid tumors have
Autor:
Neil P. Shah, Adrian Stecula, S K Tan, Elisabeth A. Lasater, J P Holmes, Catherine C. Smith, Farid F. Chehab, M Gunthorpe, Evan Massi, Andrej Sali, J Politi
Publikováno v:
Leukemia. 30:1405-1409
Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib
Autor:
Jerald P. Radich, Theodore C. Tarver, Mark J. Levis, Evan Massi, Chen-Shan Chin, Kevin Travers, Susana Wang, Adam B. Olshen, Amy L. Paguirigan, Saurabh Asthana, Catherine C. Smith, Neil P. Shah, Kimberly C. Lin, Alexander E. Perl, Grace R. Jeschke
Genomic studies have revealed significant branching heterogeneity in cancer. Studies of resistance to tyrosine kinase inhibitor therapy have not fully reflected this heterogeneity because resistance in individual patients has been ascribed to largely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b3aaff9ee4d97aea1bb6ad7c1234080
https://europepmc.org/articles/PMC5501146/
https://europepmc.org/articles/PMC5501146/
Autor:
Robert Pejchal, Rafael S. Depetris, Albert Cupo, William C. Olson, Jeong Hyun Lee, John P. Moore, Rogier W. Sanders, Nicolette Cocco, Jean-Philippe Julien, Milind Kachare, Reza Khayat, Evan Massi, Kathryn B. David, Andre J. Marozsan, Ian A. Wilson, Umesh Katpally, Andrew B. Ward
Publikováno v:
Journal of biological chemistry, 287(29), 24239-24254. American Society for Biochemistry and Molecular Biology Inc.
The trimeric envelope glycoprotein complex (Env) is the focus of vaccine development programs aimed at generating protective humoral responses to human immunodeficiency virus type 1 (HIV-1). N-Linked glycans, which constitute almost half of the molec